Zhejiang Garden Biopharmaceutical Co., Ltd. (SHE: 300401) announced that it has signed the “25‑Hydroxycholesterol New Drug R&D Project Cooperation Agreement” with Guangzhou National Laboratory — establishing a joint venture to collaboratively advance the research and development, registration, production, and commercialization of 25‑hydroxycholesterol and its prodrug class broad‑spectrum antiviral drugs, with Garden Bio holding an equity stake of no less than 51 % and leading the venture’s subsequent operations.
Transaction Snapshot
| Item | Detail |
|---|---|
| Announcing Company | Zhejiang Garden Biopharmaceutical Co., Ltd. (SHE: 300401) |
| Partner | Guangzhou National Laboratory |
| Agreement | “25‑Hydroxycholesterol New Drug R&D Project Cooperation Agreement” |
| Structure | Establishment of a joint venture |
| Scope | R&D, registration, production, and commercialization of 25‑hydroxycholesterol and its prodrug class broad‑spectrum antiviral drugs |
| Equity & Control | Garden Bio: no less than 51 %, leading subsequent operations; remaining equity held by a designated entity of Guangzhou National Laboratory |
| Market Potential | Significant potential in the broad‑spectrum antiviral field, per the announcement |
| Announcement Date | 7 Oct 2026 |
Program Profile – 25‑Hydroxycholesterol
- Candidate Drug Class: 25‑hydroxycholesterol and its prodrug class candidates, positioned as broad‑spectrum antiviral drugs.
- Therapeutic Positioning: The candidate drug possesses significant market potential in the field of broad‑spectrum antivirals — a modality of heightened strategic value for pandemic preparedness and respiratory disease defense.
- Prodrug Strategy: Development of a prodrug class around the core molecule suggests a drug‑design approach aimed at optimizing the developability and delivery of 25‑hydroxycholesterol.
- Development Stage Note: The announcement describes an R&D cooperation and joint‑venture formation; specific clinical stage, trial timelines, and target indications beyond the broad‑spectrum antiviral positioning were not disclosed.
Partner Profile – Guangzhou National Laboratory
| Item | Detail |
|---|---|
| Established | May 2021 |
| Headquarters | Guangzhou International Bio Island |
| Institution Type | New‑type scientific research institution |
| Specialization | Respiratory diseases and their prevention and control |
| Representative Breakthroughs | Leritrelvir for COVID‑19; Onlitrasvir for Influenza A; ultra‑fast PCR thermocyclers |
Guangzhou National Laboratory has previously achieved multiple major breakthroughs in antiviral drug discovery and diagnostic technology, providing the joint venture with a proven respiratory‑disease research pedigree.
Market Impact & Outlook
- Industry–Academia Commercialization Bridge: The joint venture converts national‑laboratory antiviral discovery into an industrial development pathway, pairing Guangzhou National Laboratory’s respiratory‑disease science with Garden Bio’s pharmaceutical development, production, and commercialization infrastructure.
- Controlled Consolidation: With no less than 51 % equity and operational leadership, Garden Bio secures control of the program — aligning the venture’s execution with the listed company’s strategy while retaining the laboratory’s scientific involvement through its designated entity.
- Broad‑Spectrum Antiviral Opportunity: Broad‑spectrum antivirals remain a strategically prioritized field for health systems worldwide, offering potential applicability across multiple viral threats rather than a single indication.
- Track‑Record Foundation: The laboratory’s prior successes — Leritrelvir (COVID‑19), Onlitrasvir (Influenza A), and ultra‑fast PCR thermocyclers — demonstrate end‑to‑end capability from discovery through diagnostic tooling in the respiratory space.
- Watch Items: Joint‑venture establishment and capitalization details, preclinical/clinical advancement of the 25‑hydroxycholesterol prodrug candidates, registration strategy, and future disclosure of development milestones.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the cooperation agreement and joint venture between Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory, including the research, development, registration, production, and commercialization of 25‑hydroxycholesterol and its prodrug class broad‑spectrum antiviral drugs. Actual results may differ due to risks including drug discovery and clinical development outcomes, regulatory review, joint‑venture governance and execution, manufacturing scale‑up, and competitive dynamics in the antiviral therapeutic field.-Fineline Info & Tech
